Introduction: Atheroembolization during renal artery angioplasty and stenting (RA-PTAS) has been postulated as a cause for the inferior renal function results observed when compared with those with surgical revascularization. To further characterize procedure-associated atheroembolism, we analyzed recovered atheroembolic debris and clinical data from patients undergoing RA-PTAS with distal embolic protection (DEP). Methods: RA-PTAS procedures were performed with DEP using a commercially available temporary balloon occlusion and aspiration catheter system between July 2005 and December 2006. Following RA-PTAS but prior to deflation of the distal occlusion balloon, the static column of blood proximal to the balloon was aspirated and submitted for embolic particle analysis. Angiograms, demographics, and laboratory data were reviewed. Glomerular filtration rate (eGFR) was estimated before RA-PTAS and at 4 to 8 weeks postintervention using the abbreviated Modification of Diet in Renal Disease formula. Associations between clinical factors, captured particle counts, and changes in renal function were examined using univariate techniques and multiple linear regression. Results: Twenty-eight RA-PTAS procedures were performed with DEP. Mean total number of embolic particles counted per procedure was 2033 ؎ 1553 for particles 20-60 m and 265 ؎ 132 for particles >60 m. Significant positive associations with quantity of captured particles 20 to 60 m were observed for African American race (P ‫؍‬ .002), predilation (P ‫؍‬ .005), and stent diameter (P < .001); a significant negative association was observed for preoperative aspirin use (P ‫.)610.؍‬ Quantity of captured particles >60 m was positively associated with ratio of stent to renal artery diameter (P ‫.)900.؍‬ Change in eGFR was positively associated with preoperative aspirin use (P ‫؍‬ .006) and preoperative eGFR (P < .001), while a negative association was observed for captured particle counts >60 m (P ‫؍‬ .015). 
Atherosclerotic renovascular disease (RVD) is increasingly recognized as a cause of severe secondary hypertension, renal insufficiency, and end-stage renal disease through reductions in renal blood flow. RVD represents an important public health problem as all of these associated conditions have been demonstrated to increase cardiovascular and all-cause mortality. [1] [2] [3] [4] [5] Percutaneous transluminal angioplasty and/or stenting of the renal artery (RA-PTAS) and open surgical revascularization can be used to restore perfusion to affected kidneys. RA-PTAS has become the more frequently employed treatment method in most centers and has demonstrated beneficial effects with regard to improving control of renovascular hypertension in selected patients. [6] [7] [8] [9] [10] Reported results have been less favorable, however, in terms of improving associated renal insufficiency, [6] [7] [8] [9] [10] which is the major determinant of subsequent cardiovascular morbidity and mortality as well as dialysis dependence. [11] [12] [13] Procedure-related atheroembolization has been postulated as a cause for the disparate results observed between surgical renal revascularization and RA-PTAS. [14] [15] [16] This hypothesis is supported by ex-vivo data 16 as well as observational data detailing results exceeding those of historical controls with the use of commercially available distal embolic protection (DEP) devices during RA-PTAS. 14, [17] [18] [19] [20] To date, only limited in-vivo data exist regarding the debris liberated during RA-PTAS. This report details recent analytic work investigating the characteristics of and factors associated with atheroembolic debris collected during the conduct of RA-PTAS using DEP.
METHODS
Patient population. This investigation was conducted with approval from the Wake Forest University Health Sciences Institutional Review Board. All RA-PTAS procedures were performed between July 2005 and December 2006 in patients with hemodynamically significant atherosclerotic RVD (Ն60% diameter-reducing stenosis by renal duplex ultrasonography) and severe, difficult to control hypertension with or without associated renal insufficiency.
Materials reviewed. All outpatient clinic, hospital, and endovascular operating suite records were reviewed. Collected data included patient demographics, anthropometrics, medical comorbidities, medications, laboratory results, procedure-specific data, and complications related to RA-PTAS. Percent renal artery stenosis was calculated using a method congruent with that described in the Asymptomatic Carotid Atherosclerosis Study. 21 Distal renal artery aspirates were collected at the time of RA-PTAS following angioplasty Ϯ stent placement, but prior to deflation of the distal occlusion balloon, and analyzed at the University of California at San Francisco as described below. All data were maintained in a de-identified electronic database.
Operative management. All RA-PTAS were performed in an endovascular operating suite at Wake Forest University Baptist Medical Center. Patients were admitted on the day before RA-PTAS to a 23-hour day hospital for intravenous hydration and oral administration of 600 mg N-acetylcysteine every 12 hours. Patients with severe renal insufficiency (estimated glomerular filtration rate [eGFR] Յ30 ml/min/1.73 m 2 ) were also treated with intravenous sodium bicarbonate. Only one renal artery lesion was treated at any given procedural setting. Bilateral lesions were treated in a staged fashion to minimize the volume administered and nephrotoxic effects of iodinated contrast and to avoid the potential for bilateral ischemic renal complications.
Femoral sheath access was employed for all procedures in this report and intravenous heparin administered (50 to 100 U/kg per surgeon preference) once access was secured. Iodixanol (Visipaque, Amersham Health, Princeton, NJ) was used as the intra-arterial contrast medium for all procedures. Selective renal artery cannulation was accomplished using a minimal contact technique of ostial engagement with an angled guiding catheter telescoped through a 10-cm 6 French sheath. Guidewire crossing of the lesion was performed using a commercially available temporary balloon occlusion and aspiration 0.014-inch DEP guidewire system (Guardwire, Medtronic, Minneapolis, Minn). The distal occlusion balloon was inflated in the distal main renal artery immediately after crossing the lesion and occlusion confirmed by hand injection of contrast. RA-PTAS was then performed using angioplasty balloons with or without balloon mounted stents (Genesis, Cordis, Miami FL; or Racer, Medtronic, Minneapolis Minn) of operator choice sized to match the distal, normal appearing renal artery. Predilation angioplasty was performed at the discretion of the operating surgeon with the balloon occlusion device in place and inflated. Stents were positioned to extend 1 to 2 mm into the aortic lumen while completely covering the lesion. Following angioplasty Ϯ stent deployment, the static column of blood proximal to the temporary occlusion balloon was evacuated using a rapid exchange aspiration catheter (Export catheter, Medtronic, Minneapolis Minn). Sixty ml of blood was aspirated and the aspiration catheter was then used to inject at least 20 ml of heparinized 0.9% saline to flush any residual debris from the renal artery. The temporary occlusion balloon was then deflated and completion renal arteriography was performed. Routine follow-up included clinic visits at 4 weeks, 6 months, 1 year and, then, yearly with repeat measurement of blood pressure and serum creatinine.
Specimen collection and analysis. Specimen analysis and processing was conducted at the University of California San Francisco. The initial 5 ml of aspirated blood was transferred to tubes containing 0.109 molar buffered sodium citrate (BD Vacutainer, Becton Dickinson and Company, Franklin Lakes, NJ) and stored at 4°C until particle analysis was performed.
For particle analysis, the samples were diluted in an equal volume of 0.9% saline and passed through a 20 m filter. Fragments retained on the 20 m filter were then resuspended in sterile saline and passed through a 60 m filter. Particles 20 to 60 m in diameter (contained in the effluent after passage through the 60 m filter) were sized and counted using a Coulter Counter (Beckman Multisizer 3, Beckman Coulter Inc, Fullerton Calif). Particles Ͼ60 m in diameter (retained on the 60 m filter) were removed, resuspended, counted, and categorized in 100 m increments under a light microscope at 100x magnification against a 100 m background grid. In order to estimate the relative contribution of contaminant debris to specimen particle counts, "sham" particle counts were performed on sterile saline passed through filters and resuspended in a manner identical to the handling of specimens. Due to the size-specific methods of particle number and size determination, total counts were grouped into size categories of 20 to 60 m and Ͼ60 m, reflecting the respective thresholds for use of Coulter Counter vs light microscopy methods for counting and sizing.
Renal function was evaluated using the abbreviated modification of diet in renal disease formula for eGFR calculated from pre-and postoperative serum creatinines:
Post revascularization renal function was assessed at 4-to 8-week follow-up to allow for the effects of perioperative volume expansion and contrast administration to resolve. This follow-up time point was chosen due to its coincidence with routinely scheduled follow-up employed by our group. Renal function response was categorized on a perprocedure basis as improved or worsened if a Ն20% increase or decrease in eGFR was observed, respectively. Those not meeting these criteria were defined as unchanged.
Blood pressure response was assessed using the highest measured brachial blood pressure pre-and postoperatively taken in a sitting position. Blood pressure response was defined according to previously published guidelines 23 as follows: cured -diastolic blood pressure (DBP) less than 90 mm Hg and systolic blood pressure (SBP) less than 140 mm Hg off all antihypertensive medications; improved -DBP Ͻ90 mm Hg and/or SBP Ͻ140 mm Hg on the same or reduced number of medications or a reduction in DBP of at least 15 mm Hg on the same or a reduced number of medications; failed -no change or inability to meet the criteria for cure or improvement.
Statistical methods. Descriptive statistics are reported as mean Ϯ standard deviation for continuous factors, and counts and percents for categorical factors. Associations between clinical factors and captured debris were examined using t tests for dichotomous factors and univariate regression analyses for continuous factors. Log transformations of total embolic debris counts 20 to 60 m and Ͼ60 m were analyzed to stabilize variances of those outcomes. Renal function, blood pressure, and antihypertensive agent outcomes following RA-PTAS were examined using paired t tests. Statistical significance was assessed at the 0.05 alpha-level. Log transformations of captured debris counts (20 to 60 m and Ͼ60 m), and clinical or operative predictors of blood pressure response and eGFR response to RA-PTAS were examined using multiple linear regression models. For each outcome, a "best" model was selected using a forward stepwise selection procedure where the most significant candidate variables with P-value Ͻ .15 were entered one-by-one and retained if they remained significant at the .10 level after entry. Residuals for each model were examined after variable selection to evaluate fit and look for influential observations. All statistical analyses were performed using SAS software, version 9 (SAS Institute Inc, Cary, NC).
RESULTS
Study group. Summary demographic and preoperative clinical data are displayed in Table I . Twenty-eight RA-PTAS procedures were performed with DEP in 17 female and 10 male patients with a mean age of 72.4 Ϯ 8.6 years. Mean preoperative eGFR and creatinine were 48.9 Ϯ 17.9 mL/min/1.73mL 2 and 1.49 Ϯ 0.55 mg/dL, respectively. No patient was dialysis-dependent. All patients were hypertensive (mean systolic and diastolic blood pressures were 164.1 Ϯ 21.3 and 81.3 Ϯ 9.0 mm Hg, respectively) with a mean antihypertensive agent usage of 3.4 Ϯ 1.3.
Procedural data. The 28 RA-PTAS procedures performed during the study period included 26 stent procedures and two primary angioplasty procedures (both for restenosis). Procedural data are summarized in Table II . Treated were 25 primary atherosclerotic lesions and four re-stenotic lesions (three from prior RA-PTAS and one from prior renal artery endarterectomy). Twenty-six patients were treated for unilateral disease and one for bilateral disease in a staged fashion. All treated patients had two kidneys. Mean preoperative renal artery stenosis was 70 Ϯ 12%. Mean balloon occlusion time was 15.7 Ϯ 4.3 minutes, Table III . Both preand postoperative laboratory data for determination of renal functional response at 4 to 8 weeks were available for 22/27 patients. Mean change in creatinine and eGFR were Ϫ0.14 Ϯ 0.24 mg/dL and 5.8 Ϯ 8.9 mL/min/1.73mL 2 , respectively; both were statistically significant. Renal function response was defined as improved in eight patients (36%), unchanged in 14 patients (64%), and worsened in none. Pre-vs postoperative eGFRs in the two patients with incomplete renal artery balloon occlusion were 39.2 vs 31.3 and 27.2 vs 42.1 mL/min/1.73mL 2 , respectively.
Blood pressure response at 4 to 8 weeks. Pre-and postoperative blood pressure and antihypertensive medication use are summarized in Table III . Data on blood pressure response were available for 25/27 patients. Statistically significant decreases in SBP, DBP, and number of antihypertensive agents were observed. At 4-to 8-week follow-up, blood pressure response was defined as cured in zero patients, improved in 12 (48%), and failed in 13 (52%).
Embolic particle analysis. Particle size and count data are summarized in the figure (Fig) . Mean total number of embolic particles counted per procedure was 2033 Ϯ 1553 for particles 20 to 60 m and 265 Ϯ 132 for particles Ͼ60 m. Mean "sham" total particle count was 26.5 Ϯ 10.4 (range 11 to 46). For captured particle counts 20 to 60 m, significant multivariate associations were observed with African American race (P ϭ .002), predilation (P ϭ .005), and stent diameter (P Ͻ .0001). Preoperative aspirin use was associated with significantly lower captured particle counts (P ϭ .016). For captured particles Ͼ60 m, a significant multivariate association was observed between the ratio of renal artery stent diameter to renal artery diameter (P ϭ .009) and increasing particle counts.
Mean particle counts for patients treated for restenotic lesions (N ϭ 4) were: 4121 Ϯ 2682 (Ͻ60 microns) and 298 Ϯ 132 (Ͼ60 microns). Additional multiple regression analysis excluding patients treated for restenotic lesions did not significantly affect predictors of embolic counts or renal functional outcomes. Associations between captured particle counts and renal function/blood pressure responses: In multivariate models, a significant association was observed between increasing captured particle counts Ͼ60 m and decreasing postoperative eGFR (P ϭ .015). Other significant predictors of postoperative eGFR included preoperative eGFR (P Ͻ .001) and aspirin use (P ϭ .006). No significant associations between blood pressure response (systolic or diastolic) and captured embolic particle counts were observed.
DISCUSSION
This report describes embolic debris collected from 28 RA-PTAS procedures using DEP. On average, over 2000 particles were captured per procedure. Significant associations were observed between procedural/anatomic factors and the amount of captured debris including renal stent size, preoperative aspirin use, predilation, and the ratio of renal artery stent diameter to artery diameter. Increasing captured particle counts Ͼ60 m demonstrated a significant and independent association with impaired renal function response post revascularization.
Procedure-related atheroembolism has been postulated as a factor capable of limiting the clinical results achieved with RA-PTAS. Previously published ex-vivo 16, 24, 25 and clinical data 14, [17] [18] [19] [20] have demonstrated debris liberation with a variety of angioplasty/stenting models and methods of perioperative circulatory/end-organ monitoring. [26] [27] [28] Exvivo data 16 have demonstrated the liberation of large numbers of particles with an inverse relationship between particle size and number with large numbers of released particles larger than the afferent arterioles (ϳ30 to 50 m) of the kidney. These data have also suggested that atheroembolization occurs with equal frequency during each step of a typical RA-PTAS procedure. These ex-vivo findings have been corroborated, in some areas, and expanded upon by data from a variety of clinical intraoperative monitoring and postoperative imaging studies. [26] [27] [28] The data presented in this report are consistent with the ex-vivo observations referenced above. A large number of particles were captured and quantified in blood samples retrieved from the renal artery during RA-PTAS with a temporary distal balloon occlusion and aspiration device. Previously noted relationships between particle size and number were again observed, with consistent liberation of particles large enough to occlude the microvasculature of the nephron.
Protecting the renal circulation from these embolic particles released during RA-PTAS would seem to be an obvious goal as a logical extension of these data. The potential need for such protection was anticipated by the medical device industry prior to the publication of related data. A variety of embolic protection devices have been commercially available for several years with FDA-approved indications for use in coronary saphenous vein grafts and carotid artery stenting. Use of these devices has been extended, "off-label", to RA-PTAS, and reports detailing their use have been published by several groups, including our own. 14, [17] [18] [19] [20] These authors have reported positive results in comparison with historical controls in terms of improved renal function and/or protection from renal function deterioration. These reports have also provided limited descriptions of collected debris, reporting a 44% to 100% capture of visible debris with collected particle numbers in the hundreds to thousands. The data in this report provide further corroboration of the previously reported findings and expand on existing knowledge regarding the quantity, size, and distribution of liberated embolic debris. While grossly visible debris was visible among a subset of patients, procedure-related liberation of microscopically visible debris occurred among all patients undergoing RA-PTAS. A significant rate of positive renal function response to RA-PTAS with distal embolic protection was also observed in the current sample and no short-term renal function deterioration was noted.
In an exploratory analysis of associations with captured debris, significant and independent associations were observed between captured particle counts and potential precipitants of particle liberation including predilation, renal artery stent diameter, and the ratio of renal stent to arterial diameter. Furthermore, in multiple linear regression models, a significant inverse association was observed between the quantity of collected particles Ͼ60 m in diameter and the subsequent observed change in eGFR post RA-PTAS. Several explanations for these associations exist. The positive associations with particle counts 20 to 60 m for renal artery stent diameter and predilation may represent associations with plaque volume. The association with predilation may also be indicative of particle liberation during an initial device passage and inflation in high-grade lesions. Oversizing of the stent relative to the distal renal artery may represent another potential explanation for the association with renal artery stent diameter. This argument is strengthened by the observation of a strong association between stent oversizing (relative to distal arterial diameter) and captured particle counts of debris Ͼ60 m. Numerous potential explanations also exist with regard to the observed inverse association between captured debris counts and eGFR response. One potential explanation relates to lesion characteristics; a subset of stenotic lesions may be qualitatively unstable, or "embolically prone", and liberate relatively greater amounts of debris during manipulation. As such, these lesions may have released significant quantities of debris during selective angiography and guidewire passage prior to occlusion of the renal artery using DEP, negatively impacting subsequent renal function responses. An extension of this hypothesis would be that these "embolically prone" lesions continue to shed debris through stent interstices following removal of the DEP device, providing a potential nidus for platelet aggregation and limiting early and sustained renal function response. These hypotheses are compatible with the observed association between preoperative aspirin use and eGFR response. A third potential explanation is that DEP was not effective in preventing debris passage and renal function damage. Our group favors a combination of the "embolically prone" lesion hypotheses. The lack of observed associations with other potential precipitants of embolization, such as lesion length and clopidogrel non-use, could be secondary to the limited material analyzed or the small sample size.
After controlling for preoperative eGFR, preoperative aspirin use was a significant predictor of both captured particle counts of debris 20 to 60 m and improved postoperative eGFR, while increasing number of captured fragments Ͼ60 m in diameter was associated with a significant decrease in eGFR. Interestingly, smaller particles (20 to 60 m) were not predictive of postoperative eGFR reduction in our analyses. Potential explanations exist for these differing results according to particle size. First, eGFR is an estimate of global renal function and may not be a sensitive enough measure to reflect minor reductions in single kidney function resulting from small particle embolization. Second, it is likely that particles categorized by size criteria and method of quantification may also differ in their composition (eg, cholesterol fragments, platelet aggregates and/or thrombus) and resultant end-organ effect following embolization. Finally, particles below a threshold size may have little or no effect on renal function following embolization. We suspect that a combination of these factors explain the observed associations and that further investigation, including qualitative particle analysis, is warranted.
Captured particle counts in this study were in excess of those from previous reports using the Guardwire protection device in the carotid circulation. 29, 30 This difference in mean counts may be due to intrinsic differences in anatomic and/or plaque characteristics between these two arterial locations. Alternatively, some or all of this difference may be related to the broader size range of particles counted; our analysis of particles down to a lower size minimum generated counts that were highest at the smaller end of the size range. Prior comparisons between balloon vs filter protection devices have suggested that the balloon devices are superior in capturing small particles, 30 and we continue to favor such devices at our institution for embolic protection in the renal system.
If the observed association between captured particles and renal function response is indeed valid, these data have significant implications regarding the clinical and operative management of patients with renal artery stenosis. The rationale for DEP during RA-PTAS would be further supported with the goal of optimizing renal function response, especially in light of previously published data indicating that renal function response following RA-PTAS is a key determinant of subsequent morbidity and mortality. [11] [12] [13] Furthermore, there would be technical and device specific implications. If embolic particle liberation is indeed a key event occurring at multiple successive steps of the procedure, then technical performance of RA-PTAS must be performed with minimal, gentle lesion manipulation prior to DEP device deployment. DEP devices may also require further device-specific refinement to ensure capture of the correct particle size distribution, to minimize particle liberation during device passage, and to potentially eliminate the need for lesion crossing altogether. Finally, preoperative aspirin use and avoidance of stent oversizing appeared to be important clinical factors that reduced captured debris and, by extension, could improve renal functional outcomes.
While this study provides intriguing data regarding the liberation of atheroembolic debris during RA-PTAS, numerous limitations exist that deserve comment. First, this report details an inherently incomplete analysis of liberated debris due to unavoidable limitations in debris capture. It is likely that there was considerable loss of debris into the adjacent aortic blood flow during the procedure as well as potentially incomplete evacuation through the aspiration catheter limiting the debris available for analysis. Furthermore, only five of the 60 mL of blood routinely aspirated were analyzed due to cost and resource constraints. Additionally, this investigation reports data from a modest sample of 28 RA-PTAS procedures with DEP, limiting inferential power. During aspirate collection, the particulate material was clearly mobile and easily aspirated. We believe that this material represents liberated embolic debris, but cannot be certain that the particles adherent to the luminal surface were not aspirated due to the negative pressure or possibly liberated by the aspiration catheter rather than during angioplasty and/or stenting. Our use of saline instead of peripheral blood samples to generate sham particle counts may have resulted in underestimation of the contribution of nonembolic blood components to overall counts. We intend to analyze peripheral blood samples in addition to saline in future work to determine whether a change in method is warranted. Renal function response was measured using a widely accepted GFR estimating equation based on serum creatinine values and demographics. As previously mentioned, this eGFR equation has not been validated in individuals with RVD and serum creatinine is a relatively insensitive measure of subtle renal function change. This is especially true in individuals with normal renal function, a group which was significantly represented in this sample. Finally, qualitative analysis of the liberated debris was not performed due to the small amounts of material collected; such analysis might provide further insight into the nature of procedure-related atheroembolism.
These limitations notwithstanding, this investigation provides new data regarding the occurrence of embolization during RA-PTAS and its potential limiting effects on renal function outcome. Further investigation is required to more completely define these associations as well as the appropriate role for DEP devices in the conduct of RA-PTAS.
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